Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3, randomized, investigator-blind, multi-center study to evaluate efficacy and safety of intravenous iclaprim versus linezolid in complicated skin and skin structure infections. (ASSIST-2)

Next Previous
Search
Trial Profile

Phase 3, randomized, investigator-blind, multi-center study to evaluate efficacy and safety of intravenous iclaprim versus linezolid in complicated skin and skin structure infections. (ASSIST-2)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iclaprim (Primary) ; Linezolid
  • Indications Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ASSIST-2
  • Sponsors Evolva Holding SA

Most Recent Events

  • 23 Jun 2019 According to a Motif Bio media release, results were presented at the American Society For Microbiology (ASM) Microbe 2019 meeting.
  • 26 Oct 2008 Results were presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America, according to a Arpida media release.
  • 01 Sep 2008 Data from this trial used to support a New Drug Submission to the Therapeutic Products Directorate of Health Canada, according to an Arpida media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top